Inside US FDA’s Return To In-Person Meetings

 
• By Derrick Gingery

In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.

hybrid meeting
The FDA will only allow "core participants" with speaking roles to attend hybrid meetings in person. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers